Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 337 in EWSR1-ATF1 Positive Clear Cell Sarcoma
NCT03132155Phase 2Terminated
- Sponsor
- NantPharma
- Start
- Aug 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AMG-337 in clear cell sarcoma (CCS), sponsored by NantPharma. Started Aug 2018; status: terminated.
02
Drugs
AMG-337
03
Conditions
clear cell sarcoma (CCS)
Beyond the preview
Go deeper on NCT03132155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03132155.